Alizapride HClCAS# 59338-87-3 |
- Guanfacine hydrochloride
Catalog No.:BCC1609
CAS No.:29110-48-3
- (R,R)-Formoterol
Catalog No.:BCC1293
CAS No.:67346-49-0
- Doxazosin Mesylate
Catalog No.:BCC1257
CAS No.:77883-43-3
- Medetomidine
Catalog No.:BCC1736
CAS No.:86347-14-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 59338-87-3 | SDF | Download SDF |
| PubChem ID | 135497066 | Appearance | Powder |
| Formula | C16H22ClN5O2 | M.Wt | 351.83 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 60 mg/mL (170.54 mM; Need ultrasonic and warming) | ||
| Chemical Name | 6-methoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-2H-benzotriazole-5-carboxamide;hydrochloride | ||
| SMILES | [H+].[Cl-].COc1cc2n[nH]nc2cc1C(=O)NCC3CCCN3CC=C | ||
| Standard InChIKey | BRECEDGYMYXGNF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C16H21N5O2.ClH/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2;/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Alizapride HCl Dilution Calculator
Alizapride HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8423 mL | 14.2114 mL | 28.4228 mL | 56.8456 mL | 71.057 mL |
| 5 mM | 0.5685 mL | 2.8423 mL | 5.6846 mL | 11.3691 mL | 14.2114 mL |
| 10 mM | 0.2842 mL | 1.4211 mL | 2.8423 mL | 5.6846 mL | 7.1057 mL |
| 50 mM | 0.0568 mL | 0.2842 mL | 0.5685 mL | 1.1369 mL | 1.4211 mL |
| 100 mM | 0.0284 mL | 0.1421 mL | 0.2842 mL | 0.5685 mL | 0.7106 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Alizapride HCl
- Triacontanol
Catalog No.:BCC8260
CAS No.:593-50-0
- Lindleyin
Catalog No.:BCN8450
CAS No.:59282-56-3
- Vitexin 2''-O-p-coumarate
Catalog No.:BCN2793
CAS No.:59282-55-2
- Sissotrin
Catalog No.:BCN4095
CAS No.:5928-26-7
- Decursin
Catalog No.:BCN5335
CAS No.:5928-25-6
- Acyclovir
Catalog No.:BCC3929
CAS No.:59277-89-3
- Meptazinol HCl
Catalog No.:BCC4920
CAS No.:59263-76-2
- Rigosertib sodium
Catalog No.:BCC4067
CAS No.:592542-60-4
- Rigosertib
Catalog No.:BCC4296
CAS No.:592542-59-1
- Chikusetsu Saponin Ib
Catalog No.:BCC8308
CAS No.:59252-87-8
- Laurocapram
Catalog No.:BCN8308
CAS No.:59227-89-3
- Erigeroside
Catalog No.:BCC8171
CAS No.:59219-76-0
- PIK-93
Catalog No.:BCC2519
CAS No.:593960-11-3
- Darutigenol
Catalog No.:BCN4096
CAS No.:5940-00-1
- Boc-HoSer(Bzl)-OH
Catalog No.:BCC3244
CAS No.:59408-74-1
- 1F-Fructofuranosylnystose
Catalog No.:BCN8287
CAS No.:59432-60-9
- 1-Methyl-2-undecylquinolin-4(1H)-one
Catalog No.:BCN6591
CAS No.:59443-02-6
- Monotropein
Catalog No.:BCN6280
CAS No.:5945-50-6
- Nimbin
Catalog No.:BCN4617
CAS No.:5945-86-8
- Dihydropyrocurzerenone
Catalog No.:BCN8061
CAS No.:59462-26-9
- NSC 146109 hydrochloride
Catalog No.:BCC2410
CAS No.:59474-01-0
- Tafamidis
Catalog No.:BCC5268
CAS No.:594839-88-0
- Z-D-Glu(OBzl)-OH
Catalog No.:BCC2772
CAS No.:59486-73-6
- Citric acid monohydrate
Catalog No.:BCN8492
CAS No.:5949-29-1
A new method to obtain and present complete information on the compatibility: study of its validity for eight binary mixtures of morphine with drugs frequently used in palliative care.[Pubmed:12380660]
Palliat Med. 2002 Sep;16(5):417-24.
Parenteral administration of mixtures of morphine with other drugs has become common practice in palliative care. Such mixtures are sometimes found to be incompatible but compatibility data are scarce. An attempt was made to develop a quick and simple investigation strategy to obtain complete information on the compatibility of two drugs. This strategy was then used to study the physical and chemical compatibility of morphine HCl with Alizapride HCl, atropine sulphate, dexamethasone sodium phosphate, hyoscine butylbromide, metoclopramide HCl, octreotide lactate, ranitidine HCl and hyoscine hydrobromide. These compatibility data are presented in such a way that they are easy to use in clinical practice. The investigation strategy outlined here allows the collection of complete information on the compatibility of morphine with another drug by studying a limited number of carefully selected mixtures per combination. The mixtures to be studied are selected using a scheme in which all possible mixtures prepared by mixing morphine solutions of varying concentrations with a drug solution in different volume ratios can be visualized. Applying this strategy to the eight combinations revealed, except for ranitidine HCl, no physical (visual) or chemical (HPLC; >90%) incompatibility in any of the mixtures studied for seven days at 22 and 32 degrees C. This indicates that all possible mixtures of these drug solutions with morphine HCl are compatible. For the combination with ranitidine incompatibility was observed only when using morphine HCl solutions containing >40 mg/ml and at certain ratios (drug/morphine HCl [D/M]: 4/42, 10/6 and 8/8, v/v), but all physically compatible mixtures were chemically stable (>90%). Studying extra mixtures in addition to those required to be studied according to the strategy revealed no discrepancies for any of the eight combinations studied. Adaptation of the layout of the scheme and the design of a decision tree resulted in an easy tool to check compatibility in daily practice. The scheme designed in this study is a useful tool for research and for daily practice. It simplifies and thereby encourages investigation of the compatibility of drugs. The availability of data on the physical as well as chemical compatibility in daily practice will contribute to a better quality of the mixtures used in palliative care and help to avoid complications and inadequate symptom control.
